All In MedTech

FDA Clearance Tracker · P990040-S037

TRUFILL n-BCA Liquid Embolic System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Oct 23, 2026

Approved

Time to decision

263 days

Received Feb 2, 2026. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P990040-S037
Device name
TRUFILL n-BCA Liquid Embolic System
Applicant location
Miami, FL
Received
Feb 2, 2026
Decided
Oct 23, 2026
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P990040

Device type

Device class
Class III

Every decision under product code KGG

FDA's approval statement

As written in FDA's record.

Approval of the protocol for the TRUFILL post-approval study (PAS). The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P990040/S034.

Source documents

Other decisions for Cerenovus, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.